Your browser doesn't support javascript.
loading
Polidocanol Plus Glucose Versus Glucose Alone for the Treatment of Telangiectasias: Triple Blind, Randomised Controlled Trial (PG3T).
Bertanha, Matheus; Yoshida, Winston B; Bueno de Camargo, Paula A; Moura, Regina; Reis de Paula, Dênia; Padovani, Carlos R; Sobreira, Marcone L.
Afiliación
  • Bertanha M; Department of Surgery and Orthopedics of Botucatu Medical School, São Paulo State University Júlio de Mesquita Filho, UNESP, Botucatu, SP, Brazil. Electronic address: matheusbertanha@gmail.com.
  • Yoshida WB; Department of Surgery and Orthopedics of Botucatu Medical School, São Paulo State University Júlio de Mesquita Filho, UNESP, Botucatu, SP, Brazil.
  • Bueno de Camargo PA; Department of Surgery and Orthopedics of Botucatu Medical School, São Paulo State University Júlio de Mesquita Filho, UNESP, Botucatu, SP, Brazil.
  • Moura R; Department of Surgery and Orthopedics of Botucatu Medical School, São Paulo State University Júlio de Mesquita Filho, UNESP, Botucatu, SP, Brazil.
  • Reis de Paula D; Botucatu Medical School, São Paulo State University Júlio de Mesquita Filho, UNESP, Botucatu, SP, Brazil.
  • Padovani CR; Department of Statistics of the Botucatu Biosciences Institute, São Paulo State University Júlio de Mesquita Filho, UNESP, Botucatu, SP, Brazil.
  • Sobreira ML; Department of Surgery and Orthopedics of Botucatu Medical School, São Paulo State University Júlio de Mesquita Filho, UNESP, Botucatu, SP, Brazil.
Eur J Vasc Endovasc Surg ; 61(1): 128-135, 2021 Jan.
Article en En | MEDLINE | ID: mdl-32778489
ABSTRACT

OBJECTIVE:

The aim of this study was to compare the effectiveness and safety of two sclerosing agents used to treat telangiectasias in the lower limbs 0.2% polidocanol + 70% hypertonic glucose (HG) vs. 75% HG alone.

METHODS:

A prospective, randomised, triple blind, controlled, parallel group trial with patients randomly assigned in a 11 ratio between January and December 2015, with a two month follow up, from a single academic medical centre in Brazil, was carried out. Participants were women aged 18-65 years with telangiectasias on the lateral aspect of one thigh, classified as C1EpAsPn who underwent sclerotherapy in a single session with 0.2% polidocanol + 70% HG or 75% HG alone to treat the telangiectasias on an area limited by a rectangular template. The primary effectiveness endpoint was elimination of 75% of the telangiectasias within 60 days vs. the pre-treatment pattern. The length of vessels was measured on images obtained before and after treatment using ImageJ software. Safety outcomes were analysed immediately, 7 days, and 60 days after the treatment, and included pigmentation.

RESULTS:

A total of 115 patients were included, 98 of whom completed the study. Sclerotherapy with 0.2% polidocanol + 70% HG was significantly more effective than with 75% HG alone to treat telangiectasias in the target area (82.2% vs. 63.9%; p < .001); considering a minimum improvement of 75%, there was a 0.49 risk reduction (95% confidence interval 0.24-0.98; p = .047). No severe adverse events occurred in either group. Pigmentation was the most common minor adverse event and was significantly shorter in length in the group treated with 0.2% polidocanol + 70% HG (median 0 cm vs. 0.5 cm, respectively; p = .033).

CONCLUSION:

Polidocanol 0.2% plus 70% HG had better results than 75% HG alone in sclerosing telangiectasias. No severe adverse events occurred. Pigmentation occurred in both groups and was shorter in length in the group treated with 0.2% polidocanol + 70% HG.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Soluciones Esclerosantes / Telangiectasia / Escleroterapia / Polidocanol / Glucosa Tipo de estudio: Clinical_trials Límite: Adolescent / Adult / Aged / Female / Humans / Middle aged Idioma: En Año: 2021 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Soluciones Esclerosantes / Telangiectasia / Escleroterapia / Polidocanol / Glucosa Tipo de estudio: Clinical_trials Límite: Adolescent / Adult / Aged / Female / Humans / Middle aged Idioma: En Año: 2021 Tipo del documento: Article